Phaseline

Companies › TCR2 Therapeutics

TCR2 Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Nov 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
gavo-cel (TC-210)
Autologous T cells expressing single-domain antibody against mesothelin fused to CD3-epsil
–Phase 1MesotheliomaNov 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03907852gavo-cel (TC-210)Phase 1MesotheliomaOncologyNov 2028

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.